• Deniz Can Güven, Cemal Orhan, Kazim Şahin, and Fatih M. Uçkun.
• Department of Medical Oncology, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
• Turk J Med Sci. 2020 Nov 3; 50 (SI-2): 1691-1696.

AbstractPreclinical animal models of breast cancer provide the opportunity to identify chemopreventive drugs with single-agent activity as well as effective multi-modality regimens for primary as well as secondary prevention in high-risk persons. Our group has used the 7,12-dimethylbenz(a)anthracene (DMBA) mouse model of carcinogen-induced breast cancer to explore the clinical potential of two tyrosine kinase inhibitors and a nucleoside analog as chemopreventive agents. All three agents exhibited promising preclinical activity both as monotherapy and as components of combination therapy with the standard chemotherapy drug paclitaxel. The tumors developing despite chemoprevention were not only small and grew slowly, but they also displayed a uniquely more pro-apoptotic protein expression profile. Hence, our experimental chemopreventive drugs were capable of preventing the development of aggressive mammary gland tumors with an apoptosis-resistant protein expression profile.This work is licensed under a Creative Commons Attribution 4.0 International License.

18 keywords...

hide…